Table 4.

Identification of Risk Factors for the Occurrence of TRM by Day 180 after SCT in Patients at Risk for CMV

Risk Factors	TRM at day 180		Total n = 91	P Value
	No n = 84	Yes n = 7
Age
<7 yr	40	3	43	1.00
≥7 yr	44	4	48
Disease category
Immunodeficiency	17	2	19	.60
Other	67	5	72
Disease category
Malignant	44	2	46	.30
Other	40	5	45
Donor source
Matched related donor	34	2	36	.70
Other	50	5	55
Donor source
UCB	9	0	9	1.00
Other	75	7	82
Donor source
Unrelated donor (cord or marrow)	49	5	54	.70
Matched related donor (marrow)	34	2	36
Donor source
Mismatched unrelated marrow donor	7	0	7	1.00
Matched marrow donor CMV status (recipient/donor)	67	7	74
Pos/pos	28	0	28	.02*
Pos/neg	34	2	36
Neg/pos	21	5	26
Pos/ind	1		1
CMV status (recipient/donor)
Pos/pos	28	0	28	.50
Pos/neg	34	2	36
CMV status (recipient/donor)
Pos/pos	28	0	28	.02
Neg/pos	21	5	26
Recipient CMV status
Pos	63	2	65	.02
Neg	21	5	26
Donor CMV status
Pos	49	5	54	.70
Neg	34	2	36
Receipt of TBI
Yes	33	1	34	.30
No	51	6	57
History of CMV before transplantation
Yes	5	1	6	.40
No	79	6	85
Reduced-intensity regimen
Yes	8	2	10	.20
No	76	5	81
ATG use in conditioning
Yes	22	2	24	1.00
No	62	5	67
Alemtuzumab use in conditioning
Yes	7	2	9	.10
No	77	5	82
Fludarabine use in conditioning
Yes	29	5	34	.10
No	55	2	57
ATG, alemtuzumab, or fludarabine use in conditioning
Yes	41	5	46	.40
No	43	2	45
Steroid exposure within day +50 after transplantation
Yes	41	4	45	.70
No	43	3	46
Acute GVHD
Yes	11	2	13	.30
No	73	5	78
Neutrophil engraftment within day 21
Yes	37	5	42	.20
No	47	2	49
Reactivation of CMV
Yes	25	1	26	.70
No	59	6	65
Re-reactivation of CMV
Yes	6	0	6	1.00
No	78	7	85

P value of Fisher’s exact test.

^*One patient with “pos/ind” (positive recipient but indeterminate) was not included in the Fisher’s exact test.